Navigation Links
Researchers find 'secret weapon' used by SARS virus

ino credits lead author Wataru Kamitani, a UTMB postdoctoral research fellow, with noticing that the nsp1 protein had an unexpected effect while he was investigating a different set of SARS coronavirus proteins. "He found this suppression of host gene expression, and then he designed several elegant experiments that showed it was caused by RNA degradation, something never before seen in an RNA virus."

Exactly how that degradation takes place, how an RNA virus can preserve its integrity when it makes a protein that breaks down RNA, and whether a mutated non-RNA-degrading SARS coronavirus could constitute a workable SARS vaccine are all issues that Makino's group intends to pursue. "The main concern for everybody is whether SARS will come back," Makino said. "We want to be ready for it if it does."


'"/>

Source:University of Texas Medical Branch at Galveston


Page: 1 2

Related biology news :

1. Researchers discover way to make cells in the eye sensitive to light
2. Researchers find how protein allows insects to detect and respond to pheromones
3. Researchers Uncover Key Step In Manufacture of Memory Protein
4. Researchers reveal the infectious impact of salmon farms on wild salmon
5. Researchers identify target for cancer drugs
6. Researchers discover molecule that causes secondary stroke
7. Researchers find missing genes of ancient organism
8. Researchers trace evolution to relatively simple genetic changes
9. Researchers add new tool to tumor-treatment arsenal
10. UF Researchers Map Bacterial Proteins That Cause Tooth Loss
11. VCU Researchers Identify Networks Of Genes Responding To Alcohol In The Brain
Post Your Comments:
Breaking Biology News(10 mins):ORAL COTI-2 IS EFFECTIVE IN AN ANIMAL MODEL OF HUMAN PANCREATIC CANCER 2ORAL COTI-2 IS EFFECTIVE IN AN ANIMAL MODEL OF HUMAN PANCREATIC CANCER 3ORAL COTI-2 IS EFFECTIVE IN AN ANIMAL MODEL OF HUMAN PANCREATIC CANCER 4Oramed Pharmaceuticals Reports Positive Results From a Study of Oral Insulin Capsule on Type 1 Diabetic Patients 13118 1Oramed Pharmaceuticals Reports Positive Results From a Study of Oral Insulin Capsule on Type 1 Diabetic Patients 13118 2Review of STAARs Application for the Visian 28R 29 Toric Implantable Collamer 28R 29 Lens by FDA to Resume 52197 1Review of STAARs Application for the Visian 28R 29 Toric Implantable Collamer 28R 29 Lens by FDA to Resume 52197 2Review of STAARs Application for the Visian 28R 29 Toric Implantable Collamer 28R 29 Lens by FDA to Resume 52197 3Review of STAARs Application for the Visian 28R 29 Toric Implantable Collamer 28R 29 Lens by FDA to Resume 52197 4Review of STAARs Application for the Visian 28R 29 Toric Implantable Collamer 28R 29 Lens by FDA to Resume 52197 5Swissmedic Grants Debiopharm Marketing Authorisation for Moapar 28R 29 a New Therapeutic Avenue for the Treatment of Sexual Deviations 4757 1Swissmedic Grants Debiopharm Marketing Authorisation for Moapar 28R 29 a New Therapeutic Avenue for the Treatment of Sexual Deviations 4757 2Swissmedic Grants Debiopharm Marketing Authorisation for Moapar 28R 29 a New Therapeutic Avenue for the Treatment of Sexual Deviations 4757 3